e-learning
resources
ERJ
2003
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Primary pulmonary hypertension after amfepramone (diethylpropion) with BMPR2 mutation
Abramowicz M.J., Van Haecke P., Demedts M., Delcroix M.
Source:
Eur Respir J 2003; 22: 560-562
Journal Issue:
September
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Abramowicz M.J., Van Haecke P., Demedts M., Delcroix M.. Primary pulmonary hypertension after amfepramone (diethylpropion) with BMPR2 mutation. Eur Respir J 2003; 22: 560-562
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
The definition of pulmonary hypertension: history, practical implications and current controversies
Asbestosis
Related content which might interest you:
BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives
Source: Eur Respir J 2002; 20: 518-523
Year: 2002
Genetics of pulmonary hypertension: from bench to bedside
Source: Eur Respir J 2002; 20: 741-749
Year: 2002
Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases
Source: Eur Respir J 2008; 31: 343-348
Year: 2008
Pulmonary vascular disease: an historical perspective
Source: Eur Respir Mon 2012; 57: 1-16
Year: 2012
Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats
Source: Eur Respir J 2011; 37: 813-822
Year: 2011
Targeting bone morphogenic protein receptor 2 (BMPR2) signalling to treat pulmonary arterial hypertension
Source: Eur Respir J, 50 (3) 1701370; 10.1183/13993003.01370-2017
Year: 2017
Survival with first-line bosentan in patients with primary pulmonary hypertension
Source: Eur Respir J 2005; 25: 244-249
Year: 2005
A potential new therapy for pulmonary hypertension with the use of compound 21, an angiotensin type 2 receptor (AT2R) agonist
Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments
Year: 2012
Alterations in oestrogen metabolism: implications for higher penetrance of familial pulmonary arterial hypertension in females
Source: Eur Respir J 2009; 34: 1093-1099
Year: 2009
Goal-oriented treatment and combination therapy for pulmonary arterial hypertension
Source: Eur Respir J 2005; 26: 858-863
Year: 2005
Current medical therapies in pulmonary arterial hypertension
Source: Eur Respir Mon 2012; 57: 26-41
Year: 2012
The endothelin-receptor antagonist bosentan for the treatment of pulmonary arterial hypertension (PAH) associated with congenital heart defects (CHD)
Source: Annual Congress 2004 - Treatment of pulmonary hypertension
Year: 2004
Pulmonary hypertension in COPD
Source: Eur Respir Mon 2013; 59: 189-205
Year: 2013
Outcomes of a phase II study of ACT-293987, an oral IP receptor agonist, in pulmonary arterial hypertension (PAH)
Source: Annual Congress 2010 - Present and future medical management of pulmonary arterial hypertension
Year: 2010
Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment
Source: Eur Respir J 2011; 38: 851-860
Year: 2011
Effects of endothelin receptor antagonist (ERA) bosentan on myocardial glucose metabolism in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH)
Source: International Congress 2017 – PAH and CTEPH
Year: 2017
Pathobiology of pulmonary arterial hypertension and right ventricular failure
Source: Eur Respir J 2012; 40: 1555-1565
Year: 2012
Mutations in the bone morphogenic protein receptor 2 promoter in heritable pulmonary arterial hypertension
Source: International Congress 2018 – Pathobiology of pulmonary hypertension
Year: 2018
BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease
Source: Eur Respir J 2004; 24: 371-374
Year: 2004
Serotonin transporter genes, pulmonary haemodynamics and pulmonary hypertension
Source: Annual Congress 2005 - Scientific year in review
Year: 2005
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept